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Abstract 
Background: We investigate the effect of a high dose of vitamin D3 on circulating 
concentrations of 25(OH)D3 and its metabolites 24,25(OH)2D3, 3-epi-25(OH)D3, and 
1,25(OH)2D3 in healthy individuals with self-perceived fatigue and vitamin D insufficiency 
(25(OH)D3 <50 nmol/L).  
Methods: 107 study participants (age 20–50 years) were randomized to receive a single 
100,000 IU dose of vitamin D3 (n= 52) or placebo (n= 55). Vitamin D metabolite 
concentrations in serum were measured before, and 4 weeks after, supplementation.  
Results: Overall, 52% of participants receiving vitamin D3 attained a serum 25(OH)D3 level 
>75 nmol/L. Among individuals who received vitamin D3, there were significant increases in 
serum concentrations of 25(OH)D3 and its metabolites 24,25(OH)2D3, 3-epi-25(OH)D3, and 
1,25(OH)2D3 at 4 weeks; however, inter-individual variability in these changes was 
substantial. Positive correlations between serum 25(OH)D3 and 24,25(OH)2D3 and 3-epi-
25(OH)D3, and a significant negative correlation between serum 1,25(OH)2D3 and 3-epi-
25(OH)D3, were found 4 weeks after supplementation. The 24,25(OH)2D3/25(OH)D3 and 
24,25(OH)2D3/1,25(OH)2D3 ratios were significantly increased, compared with baseline, in 
participants receiving vitamin D3. Baseline 25(OH)D3 concentration was the only factor 
predictive of the change in 25(OH)D3 after supplementation.  
Conclusions: Administration of a single high dose of vitamin D3 leads to a significant increase 
in concentrations of 25(OH)D3, 24,25(OH)2D3, 3-epi-25(OH)D3 and 1,25(OH)2D3; induction 
of the catabolic pathway predominates over the production of 1,25(OH)2D3. Due to the high 
inter-individual variation in the 25(OH)D3 response to supplementation, any given dose of 
vitamin D is unlikely to achieve optimal vitamin D status in all treated individuals 
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Introduction 
Vitamin D plays a key role in the regulation of calcium and phosphate homeostasis, and 
deficiency of this vitamin is associated with secondary hyperparathyroidism, an increase in 
bone turnover and bone loss an increased risk of several diseases, including osteoporosis, 
cardiovascular disease, diabetes and cancer [1]. Vitamin D synthesized in the skin (vitamin D3 
[cholecalciferol]) or orally ingested (either vitamin D3 or vitamin D2 [ergocalciferol]) is 
metabolized in the liver by the enzyme 25-hydroxylase (CYP2R1) to form 25-hydroxy vitamin 
D3 (25(OH)D3), which is then further metabolized primarily in the kidney by 1α-hydroxylase 
(CYP27B1) to form the active vitamin D metabolite, 1,25-dihydroxy vitamin D3 
(1,25(OH)2D3). Both 25(OH)D3 and 1,25(OH)2D3 undergo further metabolism, 
predominantly by renal 24-hydroxylase (CYP24A1), to generate 24,25-dihydroxy vitamin D3 
(24,25(OH)2 D3) and 1,24,25-trihydroxyvitamin D3 (1α,24,25(OH)3D3), respectively [2–4]. 
Mutations in the CYP24A1 gene are associated with partial or total loss of 24-hydroxylase 
activity, which in turn leads to hypercalcaemic conditions [5–7].  The production of 
24,25(OH)2D3 has been shown to be 25(OH)D3-dependent, and is moderately affected by 
vitamin D supplementation [5,6]; the physiological role of this metabolite remains to be 
established, although it is known to be involved in embryogenesis, cartilage development and 
fracture repair [8–10]. 
 
Measurement of total 25(OH)D (comprising both 25(OH)D3 and 25(OH)D2) in serum is 
widely accepted as a marker of vitamin D status; however, the optimum threshold 
concentration of 25(OH)D continues to be debated. The Institute of Medicine (IOM) 
recommends a threshold of 50 nmol/L for bone health [11], whereas the Endocrine Society 
recommend a threshold of 75 nmol/L for optimal reductions in fall or fracture risk [1]. with 
concentrations below 50 nmol/L being regarded as indicative of vitamin D insufficiency [11]..  
However, tThe 25(OH)D3 response to vitamin D supplementation varies markedly between 
individuals, and a significant proportion of patients may have persistent suboptimal levels 
despite supplementation [12–17]. Furthermore, the relationship between circulating 25(OH)D3 
concentrations and clinical outcomes such as osteoporosis and fracture risk may differ between 
racial groups, raising the question of whether 25(OH)D3 provides a reliable estimate of vitamin 
D status in all populations [18,19]. For these reasons, increasing attention is being paid to the 
measurement of 24,25(OH)2D3 (the major circulating catabolite of vitamin D), and the ratio of 
24,25(OH)2D3 to 25(OH)D3, as potential markers of vitamin D catabolism and predictors of 
the serum 25(OH)D response to vitamin D supplementation [5,6,12,18,20]. 
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Measurement of vitamin D metabolites as biomarkers of vitamin D status has been further 
complicated in recent years by the identification of C3 epimeric forms of 25(OH)D3 and 
1,25(OH)2D3 [21]. These epimers were originally identified in infants and neonates, in whom 
they account for approximately 21% of total 25(OH)D3 concentrations [21], but were 
subsequently shown to be present in lower concentrations in adults, in whom they account for 
approximately 6% of total 25(OH)D3 [21–23]. The 3-epi-25(OH)D3 metabolite is produced 
endogenously, and circulating concentrations increase following vitamin D supplementation 
[22]; however, the physiological significance of these epimers remains to be established 
[20,21]. 
 
In view of the continuing uncertainty surrounding the clinical utility of different vitamin D 
metabolites as markers of vitamin D status, and to better understand the vitamin D metabolism 
pathway in response to supplementation, the present study was performed to investigate the 
effect of a single high dose (100,000 IU) of vitamin D3 on profiles of circulating  25(OH)D3 
and its metabolites 24,25(OH)2D3, 3-epi25(OH) D3, and 1,25(OH)2D3 in healthy individuals 
with self-perceived fatigue and vitamin D insufficiency (25(OH)D3 <50 nmol/L), and to assess 
the inter-individual variability in the response to vitamin D supplementation. A further 
objective was to investigate the hypothesis that the baseline 24,25(OH)2D3/25(OH)D3 ratio is 
a predictor of the response to supplementation. 
 
 
 
Material and Methods 
 
Clinical samples 
Frozen serum samples (n=214) were obtained from a prospective randomized, double-blind, 
placebo-controlled clinical trial conducted at the University Hospital of Zurich, Switzerland 
(latitude 47° 22' N) (ClinicalTrials.gov Registry number NCT02022475). The trial was 
conducted in accordance with the declaration of Helsinki and Good Clinical Practice 
guidelines; the study protocol and its amendment were approved by the Zurich Cantonal Ethical 
Committee and Swissmedic, and informed consent was obtained from all participants prior to 
enrolment. The primary aim of the trial was to determine the effects of a single high dose of 
vitamin D3, compared with placebo, on serum 25(OH)D3 concentrations and clinical outcomes 
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such as fatigue at 4 weeks after treatment. Full details of this trial has been described elsewhere 
[23]. 
 
The trial involved 107 participants (age 20–50 years, body mass index [BMI] 18–25 kg/m2) 
who had serum 25(OH)D3 concentrations below 50 nmol/L. The 50 nmol/L threshold for 
vitamin D insufficiency was used in accordance with the recommendation of the Institute of 
Medicine (IOM) [11]. Participants were randomized to receive either a single 100,000 IU dose 
of vitamin D3 (n= 52) or placebo (n= 55).  
 
Blood samples were obtained at a screening visit immediately before treatment and at a second 
visit 4 weeks after supplementation. Serum was separated by centrifugation at 2000g for 10 
minutes, and aliquots were stored at -80°C prior to analysis. Serum concentrations of 
25(OH)D3, 3-epi 25(OH)D3, 24,25(OH)2D3 and 25-hydroxy vitamin D2 (25(OH)D2) were 
measured by a validated NIST traceable LC-MS/MS assay using a Micromass Quattro Ultima 
Pt mass spectrometer (Waters Corp., Milford, MA, USA) at Bioanalytical Facility, University 
of East Anglia, Norwich, UK; details of the assay are provided in the online supplementary 
material. For all analytes, the assay showed good linearity (r2≥0.98) and low intra-assay and 
inter-assay variability (see supplementary table S1). 
 
Measurements of total 1,25 (OH)2D3 were performed using a commercial immunoextraction 
enzyme immunoassay kit (IDS, Bolden, UK). The inter- and intra assay imprecision, as 
expressed by the coefficient of variation (CV), was less than 12.5%. Serum concentrations of 
calcium, phosphate, parathyroid hormone (PTH), C-reactive protein (CRP), and creatinine 
were measured using a Cobas 8000 analyzer (Roche Diagnostics, Mannheim, Germany) at the 
Institute of Clinical Chemistry, University Hospital of Zurich. All analyses were carried out 
according to the manufacturer’s instructions. For all analytes, intra-assay and inter-assay 
variability, as expressed by the coefficient of variation (CV), were ≤ 1.7% and 3.1%, 
respectively.  
 
Statistical analyses 
Demographic data and serum concentrations of vitamin D metabolites at baseline and follow-
up were summarized using descriptive statistics (means, SDs, medians and interquartile 
ranges). Differences between baseline and post-supplementation values were analysed by 
means of paired t tests for vitamin D metabolites, unpaired t tests for normally distributed 
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demographic variables, Mann-Whitney rank tests for non-normally distributed variables, and 
χ2 tests for categorical variables. All comparisons were two-sided. Associations between 
vitamin D3 metabolites, and other clinical variables (age, BMI, serum calcium, serum 
phosphate, and serum PTH), at baseline and at 4 weeks after supplementation were investigated 
using Spearman rank correlation analysis.  
 
Simple and multiple regression analyses were used to build prediction models for the 
25(OH)D3 response to vitamin D3 supplementation. Four different models were used: model 
1 included only baseline 25(OH)D3 concentrations as covariate; model 2 included baseline 
25(OH)D3, 24,25(OH)2D3 and 3-epi-25(OH)D3 concentrations as covariates; model 3 
included the same covariates as model 2 in addition to age, gender and body mass index (BMI), 
while model 4 included baseline 1,25(OH)2D3 concentrations in addition to the same covariates 
as model 2. All analyses were performed using IBM SPSS Statistics 22 software (SPSS Inc., 
Chicago, IL), and P values below 0.05 were considered significant. 
 
 
Results 
Baseline demographic and clinical characteristics of study participants are summarized in 
Table 1. No statistically significant differences between the vitamin D supplemented and 
placebo groups were observed. At baseline, 3-epi-25(OH)D3 was present in 88% of study 
participants, at a mean concentration equivalent to 3.9% of serum 25(OH)D3 concentrations. 
(Table 1).  
 
Changes in vitamin D metabolites following vitamin D supplementation 
Serum concentrations of vitamin D metabolites at baseline are summarized in Table 1, and 
changes in these concentrations 4 weeks after a single oral dose of 100,000 IU vitamin D3 are 
presented in Fig. 1. At 4 weeks, participants receiving vitamin D3 showed significant absolute 
increases in serum 25(OH)D3, 24,25(OH)2D3, 3-epi-25(OH)D3 and 1,25(OH)2D3 
concentrations (all P<0.001 versus baseline), whereas no such changes were seen in placebo-
treated participants.  
 
Interestingly, the ratios of 24,25(OH)2D3 to 25(OH)D3 and 24,25(OH)2D3 to 1,25(OH)3D3 
were significantly increased, compared with baseline, in study participants receiving vitamin 
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D3 supplementation (Fig. 1). The mean 24,25(OH)D3/25(OH)D3 ratio at baseline was 0.076 
± 0.02, and this had increased to 0.086 ± 0.02 (P=0.006) at 4 weeks after supplementation. 
Similarly, the ratio of 24,25(OH)2D3 to 1,25(OH)2D3 increased 2.4-fold after vitamin D3 
supplementation, from 0.023 ± 0.01 at baseline to 0.056 ± 0.025 (P<0.0001) at 4 weeks. In 
participants receiving placebo, both ratios remained unchanged following supplementation 
(P=0. 36 and P=0.92, respectively, versus baseline), as shown in Fig. 1(E and F). 
 
At 4 weeks after dosing, all participants in the vitamin D3 group had attained a serum 
25(OH)D3 concentration ≥50 nmol/L, except for one patient in whom the 25(OH)D3 
concentration increased from a baseline value of 17.5 nmol/L to 35.6 nmol/L. Overall, 52% of 
participants receiving vitamin D3 supplementation attained a serum 25(OH)D3 concentration 
of >75 nmol/L, while 46% attained a serum 25(OH)D3 concentration between 50-75 nmol/L. 
No significant differences were observed in vitamin D metabolite concentration changes from 
baseline in study subjects who attained 25(OH)D3 concentration between 50-75 nmol/L, as 
compared to those who attained a serum 25(OH)D3 concentration >75 nmol/L (Table 2).   
 
Substantial inter-individual variability in changes in serum 25(OH)D3, 3-epi-25(OH)D3, 
24,25(OH)2D3 and 1,25(OH)2D3 was observed following administration of 100,000 IU 
vitamin D3. This variability was not dependent on baseline serum levels of the respective 
analytes, as shown in Fig. 2.  
 
Overall, 25(OH)D3 accounted for approximately 89–90% of circulating vitamin D metabolites 
at baseline, 24,25(OH)2D3 accounted for 7%, and 3-epi-25(OH)D3 for approximately 3–4%. 
These proportions did not change after vitamin D3 supplementation (Fig. 3).  
 
Correlations between vitamin D3 metabolites before and after vitamin D3 supplementation 
In the overall study population (n=107), there were significant correlations at baseline between 
serum concentrations of 25(OH)D3 and 1,25(OH)2D3, 24,25(OH)2D3 or 3-epi-25(OH)D3 
(=0.39, 0.86 and 0.36, respectively; P<0.001 for all) as shown in Fig. 4. Serum concentrations 
of 24,25(OH)2D3 at baseline correlated significantly with 3-epi-25(OH)D3 (=0.37, P<0.001), 
but there were no other significant correlations between the other metabolites. There were also 
weak but significant correlations at baseline between serum 25(OH)D3 and calcium 
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concentrations (=0.24, P=0.013), and between serum 24,25(OH)2D3 and PTH concentrations 
(=0.20, P=0.043). 
 
Among participants who received vitamin D3 supplementation (n=52), there were significant 
positive correlations at 4 weeks between serum 25(OH)D3 concentrations and 24,25(OH)2D3 
(=0.47, P<0.001) and 3-epi-25(OH)D3 (=0.35, P=0.011), and a significant negative 
correlation between serum 1,25(OH)2D3 and 3-epi-25(OH)D3 (=-0.46, P<0.001). The change 
in serum 25(OH)D3 concentrations from baseline to 4 weeks after supplementation was 
significantly correlated with the change in 24,25(OH)2D3 concentrations (=0.49, P<0.0001), 
but not with changes in 1,25(OH)D2D3 concentrations (=0.05, P=0.71). 
 
 
Predictors of 25(OH)D3 response to vitamin D3 supplementation 
Multiple regression analyses were performed to identify predictors of the 25(OH)D3 response 
to vitamin D3 supplementation. The results of these analyses are summarized in Table 23. The 
variance in the 25(OH)D3 level after supplementation explained by a simple regression model 
that included only 25(OH)D3 at baseline was 15% (R2=0.17, F(1,50)=10.2, P=0.002) 
Adjustment for other vitamin D3 metabolites (1,25(OH)2D3, 24,25(OH)2D3 or 3-epi-
25(OH)D3), age, sex or BMI did not further improve the prediction of 25(OH)D3 levels after 
supplementation. Similarly, other putative markers of vitamin D3 status, including the 
24,25(OH)2D3/25(OH)D3 ratio alone or in combination with age, sex, and BMI were not 
predictive of 25(OH)D3 concentrations after vitamin D3 supplementation. None of the 
regression models could predict the variance in the 25(OH)D3 change after supplementation 
(Table 23).  
 
Changes in other circulating biomarkers of calcium homeostasis  
Participants receiving vitamin D supplementation showed a significant decrease in PTH 
concentrations at 4 weeks, whereas PTH concentrations were increased in placebo-treated 
participants (mean change -2.6 ± 13 versus 3.9 ± 18 ng/L, respectively; P=0.03). Calcium and 
phosphate concentrations remained unchanged in both groups.  
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Discussion  
This study has shown that serum concentrations of 25(OH)D3, 24,25(OH)2D3, 3-epi-
25(OH)D3 and 1,25(OH)2D3 all increase significantly 4 weeks after a single high oral dose of 
100,000 IU vitamin D3, whereas no such changes are seen in placebo-treated participants. The 
increase in 25(OH)D3 concentrations after supplementation was significantly associated with 
the increase in 24,25(OH)2D3 concentrations after supplementation. 
 
Taking the 24,25(OH)2D values and the ratio of 24,25(OH)2D/25(OH)D3 and 
24,25(OH)2D3/1,25(OH)2D3 as markers of vitamin D catabolism, we found significant 
increases in these variables following supplementation with a high dose of vitamin D3, which 
indicates induction of the vitamin D catabolic pathway. This suggests that, when adequate 
amounts of biologically active vitamin D are available, the production of the vitamin D 
catabolite 24,25(OH)D is favoured over the active metabolite 1,25(OH)D3, due to increased 
activity of 24-hydroxylase (CYP24A1), thereby avoiding excessive production of 1,25(OH)D3 
and associated toxicity. Interestingly, a previous study from our group, which analysed vitamin 
D metabolite profiles in three supplementation studies, showed that the production of 
24,25(OH)2D3 is favoured over 1,25(OH)2D3 following administration of high doses of 
vitamin D3, compared with lower doses [20]. 
 
The majority of participants receiving vitamin D3 attained serum 25(OH)D3 concentrations 
above 50 nmol/L, a widely accepted threshold for vitamin D insufficiency [11], but only 52% 
of subjects attained serum 25(OH)D3 concentrations above 75 nmol/L. This indicates that the 
use of a single high dose of vitamin D is not sufficient to ensure that adequate vitamin D levels 
are attained in all study participants. This would be consistent with the finding by Binkley et 
al [14] that suboptimal 25(OH)D3 levels persisted in approximately 20% of individuals despite 
dosing with vitamin D3, 50,000 IU monthly, for 1 year. Furthermore, our results demonstrate 
large inter-individual variations in the increase in 25(OH)D3 and 24,25(OH)2D concentrations 
following administration of 100,000 IU vitamin D3. In addition, we provide the first evidence 
that the increase in the 3-epimer 25(OH)D metabolite following vitamin D supplementation 
also shows large inter-individual variation in adults, probably due to modifying factors, as has 
previously been described for 25(OH)D3 and 24,25(OH)2D3 [5,12,14,16]. This inter-
individual variability in both 24,25(OH)D3 and 3-epi-25(OH)D3 contributes to the observed 
inter-individual variation in the response to vitamin D3 supplementation. For example, looking 
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at Fig.2, it can be seen that participants 45 and 47 in the vitamin D supplementation group had 
similar baseline concentrations of 25(OH)D3, but the increases in 24,25(OH)2D3 and 3-
epi25(OH)D3 following supplementation differed markedly between the two participants. 
These large individual variations in the response to supplementation should be taken into 
account when giving recommendations for vitamin D supplementation. Clearly, a single fixed 
dose of vitamin D will not suffice to ensure adequate 25(OH)D levels in all patients unless the 
dose is very large, thereby increasing the risk of toxicity [16]. It is therefore desirable to tailor 
the dose of vitamin D in order to achieve pre-specified 25(OH)D3 targets in individual patients 
[16].  
 
Several factors may contribute to the inter-individual variability in the response to vitamin D 
supplementation, including BMI, baseline 25(OH)D3 concentrations and genetic factors. 
Single nucleotide polymorphisms (SNPs) involved in the synthesis (DHCR7 and CYP2R1), 
binding and transportation (DBP/GC) and degradation (CYP24A1) of vitamin D and its 
metabolites have been shown to contribute to differences in the vitamin D response to 
supplementation [15,25–27].   In contrast to findings from other studies [12], the change in 
25(OH)D3 concentrations after therapy in our study was not dependent on the age and BMI of 
the study participants at baseline. This could be due to the narrow age and BMI ranges of the 
participants in our study (age: 29 ± 6 years; BMI: 22 ± 2 kg/m2).  
 
The well accepted negative correlation between baseline levels of 25(OH)D3, and the increase 
in this metabolite following supplementation [12,28], was not seen in this study. Similar 
negative findings have been reported by Binkley et al [16]. This lack of correlation in our study 
may be due to the short time period over which concentrations were measured, and the fact that 
only a single dose was used. In our regression model including only 25(OH)D3 at baseline, the 
baseline value explained 15% of the variance in the 25(OH)D3 concentration after 
supplementation. The inclusion of other vitamin D3 metabolites in the regression models did 
not improve the predictive power of baseline 25(OH)D3, and the 24,25(OH)D2D3/25(OH)D3 
ratio was not predictive of the 25(OH)D3 response.  
 
The epimeric metabolite 3-epi-25(OH)D3 was present in 88% of participants at baseline in this 
study, at a mean concentration equivalent to 3.5% of serum 25(OH)D3 concentrations. This 
finding is consistent with previous studies that found vitamin D3 epimers to be present in 
adults, albeit in lower concentrations than in infants [ 17,21,28,29]. However, the physiological 
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significance of these metabolites is unknown [21,22]. Due to the low concentrations of vitamin 
D epimers in adults, the inclusion of 3-epi-25(OH)D3 has only a marginal effect on the 
classification of vitamin D status [24]. In the present study, 3-epi-25(OH)D3 concentrations 
were not predictive of the increase in 25(OH)D3 following supplementation.  
 
To our knowledge, this is the first study to report the concentrations of key vitamin D 
metabolites following the administration of a high oral dose of vitamin D3 in young healthy 
adults with vitamin D deficiency/insufficiency. It is possible that changes in vitamin D 
metabolites after vitamin D administration might be different in the elderly as compared to 
young adults. Further studies are required to address the impact of vitamin D supplementation 
on key vitamin D metabolite concentration changes in elderly as vitamin D 
deficiency/insufficiency is more common in elderly subjects. Limitations of the study include 
the small sample size, the narrow age and BMI ranges of the participants and the short and non-
comprehensive follow-up after supplementation. As described by Binkely et al [14], following 
administration of 50,000 IU vitamin D3, 25(OH)D3 concentrations rise rapidly and reach a 
peak after 3 days, whereas in our study blood collection was only performed 4 weeks after 
dosing. An analysis of the kinetics of vitamin D catabolism by measuring changes in 
24,25(OH)2D concentrations over time following supplementation would be of great interest. 
We did not analyse the activities of enzymes involved in the enzymatic conversion of vitamin 
D metabolites (CYP27B1, CYP2R1, and CYP24A1), or polymorphisms of these enzymes. 
Moreover, we did not assess the genetic variants of vitamin D binding protein, which is well 
known to affect the response to vitamin D3 supplementation [31]. 
 
In conclusion, this study has shown that administration of a single high oral dose of vitamin 
D3 leads to a significant increase in concentrations of 25(OH)D3 and its metabolites 
24,25(OH)2D3, 3-epi (OH)D3 and 1,25(OH)2D3, with induction of the catabolic pathway 
predominating over the production of the active metabolite 1,25(OH)D3. The study has also 
highlighted the substantial heterogeneity in the 25(OH)D response to supplementation, which 
means that any given dose of vitamin D is unlikely to achieve optimal vitamin D status in all 
treated individuals. New cost-effective screening strategies are urgently needed to avoid the 
current trend toward universal supplementation on sight, and to help identify individuals 
requiring lower- or higher-dose vitamin D supplements: it should be emphasised that high 
doses of vitamin D are often counter-productive as they may not achieve an adequate increase 
in 25(OH)D.  
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Table 1 Baseline demographic and clinical characteristics 
Data are shown as mean (SD), and groups were compared using unpaired two-sided t tests, 
unless indicated otherwise.  
 
 Therapy 
n=52 
Placebo 
n=55 
P value 
Age (years) 29 (6) 28 (6) 0.30 
Gender (females/males) 27/25  
(52%/48%) 
26/29 
 (47%/53%) 
0.15a 
BMI (kg/m2) 22 (2) 22 (2) 0.54 
Arterial blood pressure (mmHg)    
Systolic 123 (11) 126 (11) 0.16 
Diastolic 78 (9) 77 (8) 0.44 
Parathyroid hormone (ng/L) 44 (16) 46 (18) 0.59 
Calcium (mmol/L)b 2.23 (0.07) 2.22 (0.07) 0.97 
Phosphate (mmol/L) 0.99 (0.18) 1.00 (0.15) 0.69 
Creatinine (µmol/L) 71 (14) 75 (13) 0.13 
C-reactive protein (mg/L)c 0.5 (0.0–1.2) 0.6 (0.3–1.8) 0.27 
24,25(OH)2D3 (nmol/L) 2.2 (0.9) 2.5 (1.0) 0.08 
25(OH)D3 (nmol/L) 28 (9) 32 (11)  0.06 
1,25(OH)2D3 (pmol/L) 100 (29) 94 (25) 0.23 
3-epi-25(OH)D3 (nmol/L) 1.0 (0.9) 1.3 (0.93) 0.08 
25(OH)D2 (nmol/L)c 1.8 (1.1–2.2) 2 (1.4–2.6) 0.06 
a2-test; bAdjusted for serum albumin concentrations; cmedian (interquartile range) 
 
 
 
 
 
 
 
 
 
18 
 
Table 2 Mean (±SD) vitamin D metabolite concentration changes from baseline in 
supplemented subjects who attained serum 25(OH)D3 concentrations between 50-75 nmol/L 
versus those who attained a serum 25(OH)D3 concentration >75 nmol/L, four weeks after a 
single oral dose of 100.000 IU vitamin D3 administration.  
 
 
Vitamin D metabolites 
50-75 nmol/L 
[n=24] 
>75 nmol/L 
[n=27] 
p-value 
25(OH)D3 [nmol/L] 39.2 ± 10.3 59.6 ± 18.9 <0.001 
24,25(OH)2D3 [nmol/L]  3.9 ± 1.2 4.9 ± 2.8 0.13 
1,25(OH)2D3 [pmol/L]  20.9 [-29.4 - 78.0]* 32.3 [-45.8 - 83-5]* 0.20* 
3-epi-25(OH)D3 [nmol/L]  1.7 ± 1.6 2.4 ± 1.9 0.17 
24,25(OH)2D3/25(OH)D3 0.091 ± 0.016 0.081 ± 0.026 0.10 
24,25(OH)2D3/1,25(OH)2D3 0.053 ± 0.017 0.060 ± 0.031 0.36 
*median [5th-95th percentile], Mann-Whitney test. 
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Table 3 Regression models for the 25(OH)D3 response to vitamin D3 supplementation 
 
 
Model Covariate Beta coefficient (95% CI) P value 
Model 1 25(OH)D3 0.41 (0.36 - 1.58) 0.002 
Model 2 25(OH)D3 0.71 (0.58 - 2.79) 0.004 
24,25(OH)2D3 -0.34 (-19.17 - 3.17) 0.156 
3-epi-(OH)2D3 -0.06 (-8.86 - 5.56) 0.648 
Model 3 25(OH)D3 0.74 (0.57 - 2.93) 0.005 
24,25(OH)2D3 -0.38 (-20.61 - 2.60) 0.125 
3-epi-(OH)2D3 -0.01 (-7.78 - 7.21) 0.939 
age -0.18 (-1.58 - 0.34) 0.203 
sex 0.005 (-11.02 - 11.40) 0.973 
BMI -0.11 (-4.05 - 1.79) 0.440 
Model 4 25(OH)D3 0.84 (0.73 - 3.21) 0.002 
24,25(OH)2D3 -0.41 (-21.3 - 1.96) 0.101 
3-epi-(OH)2D3 -0.05 (-8.61 - 5.84) 0.702 
1,25(OH)2D3 -0.15 (-0.33 - 0.11) 0.308 
  
 
Model summaries: Model 1: R2=0.17, adjusted R2=0.15, F(1,50)=10.2, P=0.002; Model 2: 
R2=0.21, adjusted R2=0.16, F(3,48)=4.3, P=0.009; Model 3: R2=0.27, adjusted R2=0.17, 
F(6,45)=4.3, P=0.023; Model 4: R2=0.23, adjusted R2=0.16, F(3,47)=4.3, P=0.014 
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Figure captions 
 
 
 
Fig. 1 Absolute changes in vitamin D metabolites from baseline (dark shading) to 4 weeks 
after (light shading) a single 100,000 IU oral dose of vitamin D3  
(A) 25(OH)D3; (B) 24,25(OH)D3; (C) 1,25 (OH)2 D3; (D) 3-epi-25(OH)D3: (E) 
24,25(OH)2D3/(25(OH)D3; (F) 24,25(OH)2D3/1.25(OH)2D3  
21 
 
 
 
 
Fig. 2 Changes in serum 25(OH)D3 [nmol/L] (A, B), 1,25(OH)2D3 [pmol/L] (C, D), (B) 
24,25(OH)2D3 [nmol/L] (E, F), (C) 3-epi-25(OH)D3 [nmol/L] (G, H) concentrations from 
baseline to 4 weeks after vitamin D supplementation in individual participants  
Open circles: baseline, black-filled circles: post-supplementation; asterisks indicate 
participants specifically referred to in the discussion.  
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Fig. 3 Relative proportions of vitamin D3 metabolites in serum at baseline (visit A) and 4 
weeks after a 100,000 IU single oral dose of vitamin D3 or placebo (visit B) 
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Fig. 4 Correlations between baseline concentrations of vitamin D metabolites.  
 
